Journey Medical (DERM) vs Jyong Biotech (MENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Journey Medical (DERM) has outperformed Jyong Biotech (MENS) over the past year, losing 31.0% versus a loss of 96.9%. Journey Medical is the larger company by market cap ($140.1 million vs $139.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | MENS |
|---|---|---|
| Share price | $4.97 | $1.84 |
| Market cap | $140.13M | $139.89M |
| 1-day change | -3.12% | -7.07% |
| YTD return | -35.60% | -53.42% |
| 1-year return | -31.04% | -96.88% |
| EPS (TTM) | $-0.22 | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $61.86M | — |
| Revenue growth (YoY) | +10.20% | — |
| Net income (latest FY) | $-11.43M | $-4.67M |
| Gross margin | 66.17% | — |
| Operating margin | -13.21% | — |
| Net margin | -18.48% | — |
| 52-week high | $9.56 | $63.00 |
| 52-week low | $4.31 | $1.43 |
| Distance from 52-week high | -48.04% | -97.08% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +176.94% | — |
| Average volume | 189.75K | 45.46K |
| Shares outstanding | 22.22M | 74.23M |
| Employees | 58 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DERM has outperformed MENS by 65.8 percentage points over the past year.
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
DERM vs MENS FAQ
Which is bigger, Journey Medical or Jyong Biotech?
Journey Medical (DERM) is larger, with a market capitalization of $140.13M compared with $139.89M for Jyong Biotech (MENS).
Which stock has performed better over the past year, DERM or MENS?
DERM returned -31.04% over the past 12 months, compared with -96.88% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Journey Medical and Jyong Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.